The company's achievements have been fully recognized by society, the government and the industry, and it has been awarded "AAA Credibility Enterprise", "Hubei's Best Investment Credit Enterprise", "Hubei Pharmaceutical Market Quality Assurance Integrity Enterprise", " "Top Ten Reputation Units in Hubei Market Industry" and other honors. In 2008, the company continued to be recognized as a "high-tech enterprise". "Wanyi" oxcarbazepine tablets were rated as "National Key New Products" and "Wuhan Independent Innovation Products", and "Dilnuo" was rated as a famous trademark of Hubei Province.
The company has more than 20 years of pharmaceutical experience, adhering to Renfu's corporate spirit of "innovation, truth-seeking, sincerity, perseverance, and unity" and taking "making safe and effective drugs and creating value for patients" as its mission. Follow the path of professional development, focus on the development of central nervous system drugs, and take into account the use of drugs for women and children. While creating value for society, shareholders and employees, we will also make outstanding contributions to human health! The company was approved as a "high-tech enterprise" in May 1992. At the end of 2000, it obtained the GMP certificate for freeze-dried powder for injection from the State Food and Drug Administration. In July 2001, it passed the GMP certification for four dosage forms: tablets, hard capsules, oral suspensions, and small-volume injections. In March and July 2003, respectively Passed GMP certification for suppositories and granules.
On February 28, 2012, Wuhan Renfu Pharmaceutical Co., Ltd. obtained the new GMP certificate issued by the Hubei Provincial Food and Drug Administration. After an on-site inspection from December 27 to 30, 2011, the company's tablets, hard capsules (including hormones), granules, oral suspensions, and suppositories in the new factory area of ??the company's oral and external preparation workshop complied with the "Good Manufacturing Practice for Drugs" (revised in 2010) requirements, and obtained the new version of the "Drug GMP Certificate" issued by the Hubei Provincial Food and Drug Administration. Obtaining this certificate marks that the company's drug quality management has reached a new level. It also lays a good foundation for accelerating the integration with international standards of drug GMP and promoting the healthy and sustainable development of the company.
The company is located at No. 7 Tujialing Road, Shaihu Di, Wuchang, Wuhan City, with convenient transportation and superior geographical location, covering an area of ??16,753.61 square meters. There is a comprehensive preparation building with a construction area of ??4885.52 square meters built in accordance with GMP requirements. It houses five domestically advanced production lines for freeze-dried powder injections, small volume injections, tablets, suppositories, granules, capsules and oral suspensions. And supporting central laboratories, air purification, central air conditioning, power supply, water supply, gas supply, refrigeration and other facilities. The company's total assets are nearly 100 million yuan.